MNKD - MannKind Corporation
| Previous Close | 1.13 |
| Open | 1.12 |
| Bid | 1.06 x 1400 |
| Ask | 1.09 x 1000 |
| Day's Range | 1.06 - 1.15 |
| 52 Week Range | 0.98 - 6.96 |
| Volume | 1,070,473 |
| Avg. Volume | 2,221,587 |
| Market Cap | 163.697M |
| Beta | 3.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Thomson Reuters StreetEvents•yesterday
Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT
Q2 2018 MannKind Corp Earnings Call
- Zacks•9 days ago
Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock?
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•11 days ago
Why MannKind Corporation Stock Is Tanking Again Today
Bad news from its Q2 results continues to plague the struggling biotech.
- InvestorPlace•12 days ago
MannKind Stock Is One Step Away From Obliteration
The second-quarter earnings season has produced plenty of shockers, and pharmaceutical company MannKind (NASDAQ:MNKD) is one of them. After posting a disastrous miss on the top-line, and financial metrics that implied a viability concern, MNKD stock tanked more than 23%. In the year-ago quarter, MannKind posted a 35-cent EPS loss.
- Motley Fool•15 days ago
Can MannKind Corporation Avert Bankruptcy?
MannKind's second-quarter numbers clearly show that the company is hanging on by a thread.
- ACCESSWIRE•15 days ago
Today's Research Reports on Trending Tickers: Tesaro and MannKind
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / U.S. equities finished mostly higher on Thursday as Apple breaching the 1 trillion dollar valuation plateau offset the ongoing trade concerns between the U.S. ...
- Zacks•15 days ago
MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and -18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- InvestorPlace•15 days ago
MannKind Corporation (MNKD) Stock Slides Despite Q2 Revenue Growth
MannKind Corporation (NASDAQ:MNKD) reported its latest quarterly earnings results after the bell Thursday, which came in ahead of its year-ago results on both its revenue and loss. For its second quarter of fiscal 2018, the biopharmaceutical company amassed net revenue of $3.8 million for its diabetes treatment Afrezza, marking a 142% growth compared to its revenue of $1.5 million from the year-ago quarter. The MannKind Corporation medication is an inhaled insulin treatment for Type 1 and Type 2 Diabetes.
- Associated Press•15 days ago
MannKind: 2Q Earnings Snapshot
On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. In the final minutes of ...
- GlobeNewswire•16 days ago
MannKind Corporation Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET
2 Q 2018 Afrezza Net Revenue was $3.8 million; 142% growth versus 2 Q 2017 2 Q 2018 Afrezza TRx grew 71% versus 2 Q 2017 Debt principal reduced by $42.6 million, or 27%, year-to-date Successfully completed ...
- GlobeNewswire•22 days ago
MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza®
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a distribution agreement for Afrezza® with Tanner Pharma Group, a global provider of integrated specialty access solutions. The agreement names Tanner as a distributor of Afrezza® outside of the United States in regions the product is not yet registered.
- GlobeNewswire•22 days ago
MannKind Corporation to Hold 2018 Second Quarter Financial Results Conference Call on August 2, 2018
WESTLAKE VILLAGE, Calif., July 27, 2018-- MannKind Corporation will host a conference call to discuss the 2018 second quarter and year-to-date financial results and other corporate developments at 5:00 ...
- Motley Fool•28 days ago
Should Biotech Investors Fear Dilution?
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
- ACCESSWIRE•last month
Free Technical Research on Marinus Pharma and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within MannKind, Healthcare Services Group, Cadence, Superior Energy Services, National Presto Industries, and New Media Investment Group — New Research Emphasizes Economic Growth
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
- GlobeNewswire•2 months ago
MannKind Set to Join Russell 3000® Index
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it is set to join the broad-market Russell 3000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on June 25, 2018, according to the final list of additions posted on June 22, 2018. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of May 11, 2018, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
- Zacks•2 months ago
Implied Volatility Surging for MannKind Corporation (MNKD) Stock Options
Investors in MannKind (MNKD) need to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•2 months ago
Additional Positive Afrezza® Clinical Data from STAT Study To Be Presented at ADA 78th Scientific Sessions
MannKind Corporation (MNKD) announced that additional data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) will be presented in an oral presentation later today at the American Diabetes Association’s (ADA) 78th Scientific Sessions. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza.
- GlobeNewswire•2 months ago
MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) announced that new data for Afrezza from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with Type 1 diabetes on multiple daily injections) were released today at the American Diabetes Association’s 78th Scientific Sessions, being held June 22-26, 2018, in Orlando, Florida. The STAT study involved 60 patients with Type 1 diabetes and is the first randomized, controlled study to use continuous glucose monitoring (CGM) with Afrezza.
- GlobeNewswire•2 months ago
MannKind to Host Institutional Investor and Analyst Meeting
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes. MannKind’ s Chief Medical Officer Presenting New Afrezza ® Data Released at American Diabetes Association’ ...
- GlobeNewswire•2 months ago
MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase
MannKind Corporation (MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administration.
- GlobeNewswire•2 months ago
MannKind Establishes Market Price Stock Purchase Plan
WESTLAKE VILLAGE, Calif., June 05, 2018-- MannKind Corporation has established a stock purchase plan that provides MannKind’ s directors and executive officers with a way to purchase shares of common stock ...
- Zacks•3 months ago
Is the Options Market Predicting a Spike in MannKind (MNKD) Stock?
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of MNKD earnings conference call or presentation 9-May-18 9:00pm GMT
Q1 2018 MannKind Corp Earnings Call
